Xiao R, Jin H, Huang F, Huang B, Wang H, Wang YG. Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape. World J Gastrointest Oncol 2024; 16(7): 2867-2876 [DOI: 10.4251/wjgo.v16.i7.2867]
Corresponding Author of This Article
Yi-Gang Wang, PhD, Professor, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 2 Street of Xiasha District, Hangzhou 310018, Zhejiang Province, China. wangyigang43@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2867-2876 Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2867
Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape
Rong Xiao, Hao Jin, Fang Huang, Biao Huang, Hui Wang, Yi-Gang Wang
Rong Xiao, Hao Jin, Biao Huang, Yi-Gang Wang, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China
Fang Huang, Department of Pathology, Laboratory Medicine Center, Zhejiang Provincial Peoples’ Hospital, Peoples’ Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Hui Wang, Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou 310018, Zhejiang Province, China
Co-corresponding authors: Hui Wang and Yi-Gang Wang.
Author contributions: Xiao R, Jin H, and Huang F performed the literature, and drafted the manuscript; Huang B, Wang H, and Wang YG revised the manuscript; and all the authors have read and approved the final version to be published.
Supported bythe Public Welfare Technology Project of Zhejiang Province, No. LGF21H160033; Zhejiang Medical Technology Plan Project, No. 2021KY047; and Hangzhou Medical Health Science and Technology Project, No. B20220173.
Conflict-of-interest statement: The authors declare that there is no conflict of interest related to this study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Gang Wang, PhD, Professor, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, No. 2 Street of Xiasha District, Hangzhou 310018, Zhejiang Province, China. wangyigang43@163.com
Received: December 28, 2023 Revised: April 24, 2024 Accepted: May 13, 2024 Published online: July 15, 2024 Processing time: 197 Days and 7.3 Hours
Abstract
Hepatocellular carcinoma (HCC) is a systemic disease with augmented malignant degree, high mortality and poor prognosis. Since the establishment of the immune mechanism of tumor therapy, people have realized that immunotherapy is an effective means for improvement of HCC patient prognosis. Oncolytic virus is a novel immunotherapy drug, which kills tumor cells and exempts normal cells by directly lysing tumor and inducing anti-tumor immune response, and it has been extensively examined as an HCC therapy. This editorial discusses oncolytic viruses for the treatment of HCC, emphasizing viral immunotherapy strategies and clinical applications related to HCC.
Core Tip: Since the discovery of oncolytic virus, various preclinical studies and clinical trials have been carried out on the application of virus therapy in hepatocellular carcinoma (HCC), and people have constantly tried to optimize the efficacy of this new drug. Based on this background, this editorial introduces oncolytic viruses for the treatment of HCC, including immunotherapy strategies, and looks forward to more good clinical results.
